Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy
sacituzumab govitecan-hziy · Immunomedics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic triple-negative breast cancer after at least two prior therapies for metastatic disease.
LAMPGEN ANALYSIS
Why it matters
Introduced a Trop-2-directed antibody-drug conjugate after multiple prior lines under accelerated approval.
What research teams should watch
Document metastatic lines and track neutropenia and diarrhea alongside treatment interruptions.
PRIMARY RECORDS